News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Kinex Pharmaceuticals Gains China Rights to Hanmi Pharmaceutical, Co., Ltd's Orascovery Program


7/15/2013 9:24:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

July 13, 2013 --Kinex Pharma of New York State extended its relationship with South Korea’s Hanmi Pharma by gaining the right to lead Hanmi’s Orascovery program development in China; Tianjin Weikai obtained exclusive China rights to manufacture and distribute TissueFlex®, a microbioreactor, from the UK’s Zyoxel; SciClone will collaborate with Soligenix of New Jersey to develop a personal medicine treatment for oral mucositis; Luqa Pharma partnered with BMG Pharma S.r.l. of Italy to bring BMG’s dermatology and oral care products to China; DelMar Pharma reported that its partner, Guangxi Wuzhou Pharma, received government support for its collaboration with DelMar; GlaxoSmithKline’s China scandals have cast a pall over the entire company’s reputation, and its problems may affect the China operations of other multinationals as well; GSK executives in China have reportedly confessed to bribing government officials, hospitals and doctors, a scheme that has been in place for “years;” GSK’s sales force in Chengdu alledgedly hatched a scheme to pay doctors to prescribe Botox, the wrinkle treatment, offering payments up to $490; and the China arm of a global trial caused a nine-month delay in the approval process of Eliquis because of errors in trial administration. More details….

Stock Symbols: (NSDQ: SCLN) (OTCQB: SNGX) (OTCQB: DMPI) (SHA: 600252) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES